Clinical Trials
21 trialsNCT07409428 2026-04-01
A Phase III Study of HMPL-760 Plus R-GemOx VS Placebo Plus R-GemOx in Relapsed/Refractory DLBCL
Hutchmed
Phase 3 Recruiting
NCT04752826 2026-02-18
MK-3475-D20
BioInvent International AB
Phase 1/2 Recruiting
NCT06580301 2026-02-06
Study of YK012 in B-cell Acute Lymphoblastic Leukemia
Excyte Biopharma Ltd
Phase 1/2 Recruiting
NCT06565689 2026-02-05
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of YK012
Excyte Biopharma Ltd
Phase 1 Recruiting
NCT07333469 2026-01-13
A Clinical Study of HX111 in Patients With Advanced Solid Tumor and Lymphoma
Hanx Biopharmaceuticals (Wuhan) Co., Ltd.
Phase 1/2 Not yet recruiting
NCT06883526 2026-01-05
Study of ZG005 in Combination With Gecacitinib in Patients With Relapsed or Refractory Lymphoma
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Phase 1/2 Recruiting
NCT06929624 2025-11-18
A Phase 3 Clinical Study of SHR-A1912 Combined With R-GemOx Versus R-GemOx in Diffuse Large B-cell Lymphoma
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 3 Recruiting
NCT07011056 2025-09-19
A Phase III Clinical Study of Purinostat Mesylate for Injection in Patients With Diffuse Large B-cell Lymphoma
Chengdu Zenitar Biomedical Technology Co., Ltd
Phase 3 Recruiting
NCT01290302 2025-06-12
Blinded Cross-Over Bioequivalence (BE) Trial of Luitpold Azacitidine vs Vidaza
American Regent, Inc.
Phase 1 Completed
NCT06601504 2025-06-06
Study of HMPL-760 Plus R-GemOx Versus Placebo Plus R-GemOx in Relapsed/Refractory DLBCL
Hutchmed
Phase 2 Active not recruiting
NCT06854445 2025-03-24
Clinical Trial of TQB2825 Injection Combined With Chemotherapy in Subjects With Diffuse Large B-cell Lymphoma
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2 Recruiting
NCT06792253 2025-01-24
Study Comparing BEBT-908 Combined With R to SOC for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
BeBetter Med Inc
Phase 3 Recruiting
NCT02653976 2024-01-26
A Phase 2 Study of SP-02L in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
Solasia Pharma K.K.
Phase 2 Completed
NCT06164327 2023-12-11
Study of BEBT-908 Combined With Drugs in the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
BeBetter Med Inc
Phase 1 Unknown
NCT06082596 2023-10-13
Study of BEBT-908 in Subjects With Advanced Hematological Tumors
BeBetter Med Inc
Phase 1 Completed
NCT06074107 2023-10-11
Study of BEBT-908 in the Relapsed or Refractory Diffuse Large B-cell Lymphoma Subjects
BeBetter Med Inc
Phase 2 Unknown
NCT03709914 2023-09-15
Pediatric_PK
Nabriva Therapeutics AG
Phase 1 Unknown
NCT02223052 2020-05-12
Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies
Celgene
Phase 1 Completed
NCT01435863 2015-08-13
A Phase 1 Study of SP-02L in Relapsed or Refractory Patients With Peripheral T-cell Lymphoma (PTCL)
Solasia Pharma K.K.
Phase 1 Completed
NCT01689220 2014-09-04
A Phase 1 Study of SP-02L in Relapsed or Refractory Patients With Peripheral T-cell Lymphoma (PTCL) in Korea
Solasia Pharma K.K.
Phase 1 Completed
NCT01148108 2013-03-15
Study of Canfosfamide in Refractory or Relapsed Mantle Cell, Diffuse Large B Cell Lymphoma and Multiple Myeloma
Telik
Phase 2 Completed